Income statement
USD
Annual
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 9M | 10M | 9M | 10M | 13M |
| Gross Profit | 2M | 3M | 3M | 1M | 6M |
| Operating Income | -7M | -6M | -7M | -9M | -5M |
| EBITDA | -8M | -5M | -5M | -8M | -5M |
| Net Income | -18M | -11M | -11M | -16M | -9M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.0001
+0.00% today
1Y Change
+0.00%
Window
Jun 23, 2025 → Jun 19, 2026
Coverage: 255 bars · Jun 23, 2025 → Jun 19, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
ThermoGenesis Holdings, Inc. (THMO) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 23, 2025 → Jun 19, 2026). Baseline metrics include revenue growth of -9.9%, EPS growth of +62.9%, a dividend yield of 0.0%. What stands out right now is revenue -9.9%, EPS +62.9%, free cash flow +29.0% with operating margin -69.6% and ROIC -92.3%. Valuation is more restrained than many high-expectation growth names at price/sales 0.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines THMO price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
THMO
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
THMO Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for THMO and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$13.0M
+33.9% YoY
FY Net Income
-$9.5M
+41.9% YoY
Free Cash Flow
-$3.4M
+76.1% YoY
Revenue Growth
-9.9%
EPS Growth
+62.9%
Gross Margin
20.4%
Net Margin
-190.3%
Income statement
USD
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 9M | 10M | 9M | 10M | 13M |
| Gross Profit | 2M | 3M | 3M | 1M | 6M |
| Operating Income | -7M | -6M | -7M | -9M | -5M |
| EBITDA | -8M | -5M | -5M | -8M | -5M |
| Net Income | -18M | -11M | -11M | -16M | -9M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Cash & Equivalents | 2M | 4M | 7M | 7M | 3M |
| Total Assets | 11M | 19M | 21M | 21M | 15M |
| Total Liabilities | 15M | 16M | 17M | 15M | 14M |
| Shareholder Equity | -2M | 4M | 4M | 6M | 386K |
| Total Debt | 11M | 10M | 10M | 8M | 6M |
| Net Debt | 9M | 6M | 3M | 517K | 3M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
3M
+77.4% YoY
Capital Expenditures
182K
-691.3% YoY
Free Cash Flow
3M
+76.1% YoY
Key ratios
Gross Margin
20.4%
Operating Margin
-69.6%
Net Margin
-190.3%
ROE
-1367.4%
Debt / Equity
-6.33x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.